EF-Tu Targeting Antibody for Infection Treatment
Application
Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections.
Key Benefits
An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections.
A research-grade antibody has been developed with animal data showing the ability to...
Published: 10/13/2023
Contributor(s): Joanna Goldberg, Dina Moustafa
|
Generation of Vaccines Preventing the Common Cold
Application
A new class of vaccines targeting the viruses causing the common cold, rhinoviruses (RV).
Key Benefits
Capsid-chimeric strains for developing new RV vaccines.
Preclinical data with a prototype show the ability to induce a robust capsid-specific immune response.
Straightforward and inexpensive vaccine manufacturing process utilizing...
Published: 1/17/2024
Contributor(s): Sujin Lee
|
RSV Vaccine for Infants and Children
Application
Vaccine for Respiratory Syncytial Virus (RSV) in infants and children.
Key Benefits
A novel vaccine targeting both the F and G proteins of the respiratory syncytial virus (RSV), including its variants.
Preliminary data in in mice show the vaccine induced the production of antibodies associated with preventing disease.
Potential to...
Published: 3/1/2024
Contributor(s): Larry Anderson, Binh Ha, Heying Sun
|
BG505 SOSIP Vaccine Elicited Neutralizing Monoclonal Antibodies for HIV
Application
ELISA
Western Blot
Immunohistochemistry
Specficity
HIV-1 BG505 Env protein (clone name: YRK01, YRK02).
Subtype
Monoclonal antibody.
Immunogen
HIV-1 BG505 SOSIP Env trimer.
Technical Summary
HIV-1 envelope glycoprotein (Env) is a membrane protein complex involved in receptor recognition and viral fusion with CD4+ T cells...
Published: 3/1/2024
Contributor(s): Cynthia Derdeyn, Tysheena Charles
|
Extended Efficacy SARS-COV-2 Vaccine
Application
A vaccine for SARS-COV-2 that can be used to protect against infection by future forms of Variant-of-Concern (VOC) or other SARS-like coronaviruses.
Key Benefits
An approach to developing a vaccine that would be effective against future mutations of SARS-COV-2.
A vaccine that elicits an immune response to conserved portions...
Published: 3/1/2024
Contributor(s): Chinglai Yang, Ling Ye, Samuel Stampfer, Rui Jin
|
HIV-1 Clade C Protein Immunogen as HIV-1 Vaccine
Application
Novel stabilized HIV-1 Clade C gp140 trimeric immunogen useful as a vaccine.
Key Benefits
Vaccine for HIV-1 infections.
Induces both neutralizing and V1V2 scaffold directed antibody responses.
V1V2 scaffold directed antibodies bind to multiple strains of HIV-1 from different clades including Clades B and C.
Market Summary
HIV-1...
Published: 3/1/2024
Contributor(s): Rama Rao Amara, Sailaja Gangadhara, Tiffany Styles, Anusmita Sahoo
|
Live Attenuated Zika Virus Vaccines
Application
Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines.
Key Benefits
Reduces neurotropism from Zika virus.
High safety and immunogenicity of chimeric vaccines.
Market Summary
Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 11/6/2023
Contributor(s): Baek Kim
|
Boosting Immunogenicity of Vaccines Using Saponins and Agonists of the Intracellular STING Pathway
Application
Vaccine formulation of an activator of the stimulator of interferon genes (STING) pathway and saponin adjuvant for enhanced protection of aged population.
Key Benefits
Significantly improved protective immunity of vaccine in the aged.
More efficient than the current methods of influenza vaccination of population 65 years of age or...
Published: 3/1/2024
Contributor(s): Elena Vassilieva, Richard Compans
|
Virus-Like Particles as RSV Vaccine Candidate
Application
Virus-like particle (VLP) vaccine candidate(s) to prevent respiratory syncytial virus (RSV) infection.
Key Benefits
Candidates may have the most effective anti-viral and anti-inflammatory response.
Potentially protects elderly and immunocompromised patients from re-infection with the RSV virus.
Efficient, tunable and stable production...
Published: 3/11/2024
Contributor(s): Binh Ha, Larry Anderson, Elizabeth Wright
|
Trimeric Immunogen for HIV-1 Vaccination
Application
Trimeric gp120 immunogen that induces broadly cross-reactive V1V2-antibodies for HIV-1 vaccine.
Key Benefits
Possible oral administration.
Broadly cross-reactive against HIV-1 panel.
Promotes antibody responses as both a primary immunogen and boosting immunogen.
Market Summary
Antiretroviral therapy (ART) has dramatically prolonged...
Published: 9/6/2023
Contributor(s): Rama Amara, Andrew Jones, Raghavan Varadarajan, Sannula Kesavardhana
|